Axsome Therapeutics, Inc. $AXSM Holdings Decreased by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P trimmed its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 2.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 277,465 shares of the company’s stock after selling 6,705 shares during the period. Loomis Sayles & Co. L P’s holdings in Axsome Therapeutics were worth $28,965,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of AXSM. Bank of New York Mellon Corp lifted its position in Axsome Therapeutics by 55.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 203,632 shares of the company’s stock worth $21,257,000 after buying an additional 72,609 shares in the last quarter. Nuveen LLC acquired a new position in shares of Axsome Therapeutics in the first quarter worth $48,185,000. Jump Financial LLC purchased a new stake in shares of Axsome Therapeutics during the first quarter worth $10,805,000. Los Angeles Capital Management LLC boosted its position in Axsome Therapeutics by 154.5% during the second quarter. Los Angeles Capital Management LLC now owns 4,424 shares of the company’s stock valued at $462,000 after purchasing an additional 2,686 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its position in Axsome Therapeutics by 33.3% during the first quarter. Affinity Asset Advisors LLC now owns 100,000 shares of the company’s stock valued at $11,663,000 after purchasing an additional 25,000 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on AXSM shares. Royal Bank Of Canada upped their target price on Axsome Therapeutics from $189.00 to $198.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 4th. Morgan Stanley increased their price objective on Axsome Therapeutics from $194.00 to $196.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. B. Riley initiated coverage on shares of Axsome Therapeutics in a research report on Wednesday, October 1st. They set a “buy” rating and a $179.00 price objective on the stock. Mizuho boosted their target price on shares of Axsome Therapeutics from $200.00 to $202.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, Bank of America increased their price target on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the stock a “buy” rating in a research note on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $179.88.

Axsome Therapeutics Stock Up 0.4%

AXSM opened at $151.56 on Friday. The firm has a market cap of $7.64 billion, a P/E ratio of -29.89 and a beta of 0.50. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.51 and a current ratio of 1.57. The business has a 50 day moving average price of $131.99 and a 200 day moving average price of $117.46. Axsome Therapeutics, Inc. has a twelve month low of $75.56 and a twelve month high of $152.94.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The firm had revenue of $170.99 million during the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics’s revenue for the quarter was up 63.2% compared to the same quarter last year. Research analysts forecast that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 91,705 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $132.34, for a total transaction of $12,136,239.70. Following the completion of the transaction, the chief executive officer owned 7,229 shares of the company’s stock, valued at $956,685.86. The trade was a 92.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Mark L. Jacobson sold 45,783 shares of the stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $114.48, for a total value of $5,241,237.84. The disclosure for this sale is available in the SEC filing. Insiders have sold 350,577 shares of company stock worth $43,803,199 in the last quarter. 22.30% of the stock is currently owned by company insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.